Compare Johnson & Johnson (JNJ) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Johnson & Johnson trades at $248.08 (market cap $598.96B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.61. The key difference: Johnson & Johnson pays a 2.15% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| JNJ | USIG | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Fixed Income |
52-Week High | $267.24 | $52.69 |
52-Week Low | $164.36 | $50.50 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
USIG (iShares Broad USD Investment Grade Corporate Bond ETF) trades at $50.605, down 0.27% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings with RSI at 51.10. Recent corporate actions include dividend payments of $0.20-$0.21 per share. Short interest surged 63.4% in April 2026, indicating growing bearish sentiment among traders.
The ETF faces headwinds from rising short interest and bearish technical positioning. Investment grade corporate bond exposure provides stability but current market sentiment suggests caution. The dividend yield remains modest while technical indicators point to potential near-term pressure on the share price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
